Matches in Nanopublications for { <http://www.w3.org/2000/01/rdf-schema#SENTENCE> ?p ?o ?g. }
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "the anti-inflammatory drugs methyl prednisolone and dexamethasone, used for Covid-19 patients dexamethasone are methide quinones, and possess only one carbonyl moiety, instead of two for Embelin, a quinone natural product." provenance.
- SENTENCE label "the anti-inflammatory drugs methyl prednisolone and dexamethasone, used for Covid-19 patients dexamethasone are methide quinones, and possess only one carbonyl moiety, instead of two for Embelin, a quinone natural product." provenance.
- SENTENCE label "the anti-inflammatory drugs methyl prednisolone and dexamethasone, used for Covid-19 patients dexamethasone are methide quinones, and possess only one carbonyl moiety, instead of two for Embelin, a quinone natural product." provenance.
- SENTENCE label "the anti-inflammatory drugs methyl prednisolone and dexamethasone, used for Covid-19 patients dexamethasone are methide quinones, and possess only one carbonyl moiety, instead of two for Embelin, a quinone natural product." provenance.
- SENTENCE label "the anti-inflammatory drugs methyl prednisolone and dexamethasone, used for Covid-19 patients dexamethasone are methide quinones, and possess only one carbonyl moiety, instead of two for Embelin, a quinone natural product." provenance.
- SENTENCE label "the anti-inflammatory drugs methyl prednisolone and dexamethasone, used for Covid-19 patients dexamethasone are methide quinones, and possess only one carbonyl moiety, instead of two for Embelin, a quinone natural product." provenance.
- SENTENCE label "the anti-inflammatory drugs methyl prednisolone and dexamethasone, used for Covid-19 patients dexamethasone are methide quinones, and possess only one carbonyl moiety, instead of two for Embelin, a quinone natural product." provenance.
- SENTENCE label "the anti-inflammatory drugs methyl prednisolone and dexamethasone, used for Covid-19 patients dexamethasone are methide quinones, and possess only one carbonyl moiety, instead of two for Embelin, a quinone natural product." provenance.
- SENTENCE label "Based on these findings, dexamethasone (Dex)-target complexes were used to perform MD simulations to analyze dexamethasone (Dex) stability at 50 ns." provenance.
- SENTENCE label "Based on these findings, dexamethasone (Dex)-target complexes were used to perform MD simulations to analyze dexamethasone (Dex) stability at 50 ns." provenance.
- SENTENCE label "Based on these findings, dexamethasone (Dex)-target complexes were used to perform MD simulations to analyze dexamethasone (Dex) stability at 50 ns." provenance.
- SENTENCE label "Based on these findings, dexamethasone (Dex)-target complexes were used to perform MD simulations to analyze dexamethasone (Dex) stability at 50 ns." provenance.
- SENTENCE label "Based on these findings, dexamethasone (Dex)-target complexes were used to perform MD simulations to analyze dexamethasone (Dex) stability at 50 ns." provenance.
- SENTENCE label "Based on these findings, dexamethasone (Dex)-target complexes were used to perform MD simulations to analyze dexamethasone (Dex) stability at 50 ns." provenance.
- SENTENCE label "Based on these findings, dexamethasone (Dex)-target complexes were used to perform MD simulations to analyze dexamethasone (Dex) stability at 50 ns." provenance.
- SENTENCE label "Based on these findings, dexamethasone (Dex)-target complexes were used to perform MD simulations to analyze dexamethasone (Dex) stability at 50 ns." provenance.
- SENTENCE label "Based on these findings, dexamethasone (Dex)-target complexes were used to perform MD simulations to analyze dexamethasone (Dex) stability at 50 ns." provenance.
- SENTENCE label "Based on these findings, dexamethasone (Dex)-target complexes were used to perform MD simulations to analyze dexamethasone (Dex) stability at 50 ns." provenance.
- SENTENCE label "The therapeutic effect of dexamethasone may be related to dexamethasone's ability to improve cortical function." provenance.
- SENTENCE label "The therapeutic effect of dexamethasone may be related to dexamethasone's ability to improve cortical function." provenance.
- SENTENCE label "The therapeutic effect of dexamethasone may be related to dexamethasone's ability to improve cortical function." provenance.
- SENTENCE label "The therapeutic effect of dexamethasone may be related to dexamethasone's ability to improve cortical function." provenance.
- SENTENCE label "The therapeutic effect of dexamethasone may be related to dexamethasone's ability to improve cortical function." provenance.
- SENTENCE label "The therapeutic effect of dexamethasone may be related to dexamethasone's ability to improve cortical function." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.
- SENTENCE label "Notably, the current recommended drugs for the treatment of severe COVID-19, dexamethasone and remdesivir, may cause hyperglycemia, an adverse effect that physicians should bear in mind, when caring for patients with diabetes mellitus (DM) and coronavirus disease 2019 (COVID)-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS)-CoV-2)." provenance.